tradingkey.logo
搜索

Glaukos Corp

GKOS
添加自选
144.420USD
0.0000.00%
收盘 06/26, 16:00美东报价延迟15分钟
8.43B总市值
亏损市盈率 TTM

Glaukos Corp

144.420
0.0000.00%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

0.00%

5天

+10.51%

1月

+25.62%

6月

+24.28%

今年开始到现在

+27.91%

1年

+42.91%

关键数据
--今开
0.000最高
0.00成交量
亏损市盈率 TTM
290.59市盈率动
--股息TTM
3.41%换手率
144.420昨收
0.000最低
0.00成交额
亏损市盈率静
12.56市净率
0.00%股息率 TTM
-20.36%ROA
148.11052周最高
2.56量比
-146.37M净利润
58.36M总股本
-3.3024每股收益TTM
0.86Beta
-26.39%ROE
73.16052周最低
2.87%振幅
77.86%毛利率
8.43B总市值
11.61回报/风险
2.91%风险率

TradingKey Glaukos Corp股票评分

单位: USD 更新时间: 2026-06-26

操作建议

Glaukos Corp当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名4/203位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价158.33。中期看,股价处于上升通道。近一个月,市场表现很强,技术面和基本面综合得分较高,很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Glaukos Corp评分

相关信息

行业排名
4 / 203
全市场排名
28 / 4566
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
极度看好

Glaukos Corp亮点

亮点风险
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
业绩高增长
公司营业收入稳步增长,连续3年增长61.24%
利润高增长
公司净利润处于行业前列,最新年度总收入507.44M美元
估值合理
公司最新PE估值-43.73,处于3年历史合理位
机构减仓
最新机构持股59.35M股,环比减少4.48%

分析师目标

根据 15 位分析师
买入
评级
158.333
目标均价
+11.06%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Glaukos Corp新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Glaukos Corp简介

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
公司代码GKOS
公司Glaukos Corp
CEOBurns (Thomas William)
网址https://www.glaukos.com

常见问题

Glaukos Corp(GKOS)的当前股价是多少?

Glaukos Corp(GKOS)的当前股价是 144.42。

Glaukos Corp的股票代码是什么?

Glaukos Corp的股票代码是GKOS。

Glaukos Corp股票的52周最高点是多少?

Glaukos Corp股票的52周最高点是148.11。

Glaukos Corp股票的52周最低点是多少?

Glaukos Corp股票的52周最低点是73.16。

Glaukos Corp的市值是多少?

Glaukos Corp的市值是8.48B。

现在Glaukos Corp(GKOS)的股票是买入、持有还是卖出?

根据分析师评级,Glaukos Corp(GKOS)的总体评级为买入,目标价格为158.33。

Glaukos Corp(GKOS)股票的每股收益(EPS TTM)是多少

Glaukos Corp(GKOS)股票的每股收益(EPS TTM)是-3.28。
KeyAI